Kiora Pharmaceuticals (KPRX) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kiora Pharmaceuticals is the larger company by market cap ($3.2 million vs $3.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KPRX | SKYE |
|---|---|---|
| Share price | $0.7202 | $0.70 |
| Market cap | $3.19M | $3.10M |
| 1-day change | -12.28% | -11.03% |
| YTD return | -63.44% | — |
| 1-year return | -61.49% | — |
| 5-year return | -99.87% | — |
| EPS (TTM) | $-2.72 | $-7.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-10.84M | $-55.92M |
| 52-week high | $2.91 | $11.04 |
| 52-week low | $0.72 | $0.484 |
| Distance from 52-week high | -75.25% | -93.66% |
| Analyst consensus | none | none |
| Avg. price target upside | +1566.20% | +9614.29% |
| Average volume | 35.23K | 88.19K |
| Shares outstanding | 4.42M | 4.42M |
| Employees | 13 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kiora Pharmaceuticals
KPRX stock →Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
KPRX vs SKYE FAQ
Which is bigger, Kiora Pharmaceuticals or Skye Bioscience?
Kiora Pharmaceuticals (KPRX) is larger, with a market capitalization of $3.19M compared with $3.10M for Skye Bioscience (SKYE).
Are Kiora Pharmaceuticals and Skye Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.